Development of compounds actives in insomnia: Recent developements and methodological aspects;Développement de molécules actives dans l'insomnie: Actualités et aspects méthodologiques

Revue Neurologique

Volumn 159, Issue 11 SUPPL., 2003, Pages

  Staner, L ^a   Luthringer, R ^a   Macher, J P ^a  

^a FORENAP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPNOTIC SEDATIVE AGENT;

CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DRIVING ABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; GABAERGIC SYSTEM; HUMAN; HYPNOSIS; INSOMNIA; NEUROLOGIC EXAMINATION; POLYSOMNOGRAPHY; PSYCHOMOTOR PERFORMANCE; SIDE EFFECT; SIMULATION; SLEEP INDUCTION; SPECTROSCOPY;

BENZODIAZEPINES; CIRCADIAN RHYTHM; CLINICAL TRIALS; DRUG DESIGN; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPNOTICS AND SEDATIVES; PATIENT SELECTION; POLYSOMNOGRAPHY; RECEPTORS, GABA-A; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; WAKEFULNESS;

EID: 0345307234     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. AMERICAN PSYCHIATRIC ASSOCIATION (APA). (1994). Diagnostic and Statistical Manual of Mental Disorder, fourth edition, Washington DC.
2. AMERICAN SLEEP DISORDER ASSOCIATION (ASDA). (1990). The International Classification of Sleep Disorders: Diagnostic and Coding Manual, Rochester, Minnesota, American Sleep Disorder Association.
3. ASTON-JONES G, CHEN S, ZHU Y, OSHINSKY ML. (2001). A neural circuit for circadian regulation of arousal. Nat Neurosci, 4: 732-8.
4. BENINGTON JH, KODALI SK, HELLER HC. (1995). Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res, 692: 79-85.
5. BEUCKMANN CT, YANAGISAWA M. (2002). Orexins: from neuropeptides to energy homeostatis and sleep/wake regulation. J Mol Med, 80: 329-42.
6. BIXLER EO, KALES A, SOLDATOS CR, KALES JD, HEALEY S. (1979). Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry, 136: 1257-62.
7. BONNET MH, ARAND DL. (1997). Hyperarousal and insomnia. Sleep Med Rev, 1: 97-108.
8. BONNET MH, ARAND DL. (1998). Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med, 60: 610-5.
9. BORBELY AA, TOBLER I. (1989). Endogenous sleep promoting substance and sleep regulation. Physiol Rev, 69: 605-70.
10. CAMPBELL IG, FEINBERG I. (1999). Comparison of MK-801 and sleep deprivation effects on NREM, REM and waking spectra in the rat. Sleep, 22: 423-32.
11. CLUYDTS R, DE ROECK J, COSYSNS P, LACANTE P. (1995). Antagonising the effects of experimentally induced sleep disturbance in healthy volunteers by lormetazepam and zolpidem. J Clin Psychopharmacol, 15: 132-7.
12. 2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol, 171: 207-18.
13. A agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. Psychopharmacology, 130: 285-91.
14. FORD DE, KAMEROW DB. (1989). Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA, 162: 1479-84.
15. FULDA S, SCHULZ H. (2001). Cognitive dysfunction in sleep disorders. Sleep Med Rev, 5: 423-45.
16. GOTTESMANN C. (2002). GABA mechanisms and sleep. Neuroscience, 111: 231-9.
17. GRONFIER C, LUTHRINGER R, FOLLENIUS M, SCHALTENBRAND N, MACHER JP, MUZET A, BRANDENBERGER G. (1996). A quantitative evaluation of the relationships between growth hormone secretion and delta wave electroencephalographic activity during normal sleep and after enrichment in delta waves. Sleep, 19: 817-24
18. A receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep, 22: 33-42.
19. LANDOLT HP, MEIER V, BURGESS HJ, FINELLI LA, CATTELIN F, ACHERMANN P, BORBELY AA. (1999). Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology, 21: 455-66.
20. A1a receptors. Involvement in sleep regulation and potential of selective agonists in the treatment of insomnia. CNS Drugs, 13: 185-99.
21. MAITRE M. (1997). The γ-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol, 51: 337-61.
22. MATHIAS S, STEIGER A, LANCEL M. (2001). The GABAa agonist gaboxadol improves the quality of post-nap sleep. Psychopharmacology, 157: 299-304.
23. MATHIAS S, WETTER TC, STEIGER A, LANCEL M. (2001). The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging, 22: 247-53.
24. MC NAIR DM, LORR M, DROPPLEMAN LF. (1971). EITS manual for the Profil of Mood States. San Diego, CA, Educational and Industrial Testing Service.
25. MELLINGER GD, BALTER MB, UHLENHUTH EH. (1985). Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry, 42: 225-232.
26. MENDELSON WB. (2002). Melatonin microinjection into the medial preoptic area increases sleep in the rat. Life Sci, 71: 2067-70.
27. MIGNOT E, TAHERI S, HISHINO S. (2002). Sleeping with the hypothalamus: emerging therapeutics targets for sleep disorders. Nat Neurosci, 5: 1071-5.
28. MÖHLER H, FRITSCHY JM, RUDOLPH U. (2002). A new benzodiazepine pharmacology. J Pharmacol Exp Ther, 300: 2-8.
29. OHAYON M. (1996). Epidemiologic study on insomnia in the general population. Sleep, 19: S7-S15.
30. e révision (CIM-10), OMS, Genève.
31. PARROT AC, HINDMARCH I. (1980). The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations. A review. Psychopharmacology, 71: 173-9.
32. PERLIS ML, KEHR EL, SMITH MT, ANDREWS PJ, ORFF H, GILES DE. (2001). Temporal and stagewise distribution of high frequency activity in patients with primary and secondary insomnia and in good sleeper control. J Sleep Res, 10: 93-104.
33. ROTH T, ROEHRS T, VOGEL G. (1995). Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep, 18: 246-51.
34. SACK RL, HUGHES RJ, EDGAR DM, LEWY AJ. (1997). Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep, 20: 908-15.
35. SAPER CB, CHOU TC, SCAMMEL TE. (2001). The sleep switch: hypothalamic control of sleep and wakefulness. TINS, 24: 726-31.
36. SCAMMELL TE, GERASHCHENKO DY, MOCHIZUKI T et al. (2001). An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience, 107: 653-63.
37. SOFFIN EM, EVANS ML, GILL CH, HARRIES MH, BENHAM CD, DAVIES CH. (2002). SB-334867-A antagonises orexin mediated axcitation in the locus coeruleus. Neuropharmacology, 42: 127-33.
38. STANER L, MAURICE D, CORNETTE F et al. (2002). Sleep microstructure around sleep onset in primary insomnia and major depressive insomnia. J Sleep Res, 11: 214-5.
39. STERIADE M. (2000). Corticothalamic resonance, states of vigilance and mentation. Neuroscience, 101: 243-76.
40. STONE BM, TURNER C, MILLS SL, NICHOLSON AN. (2000). Hypnotic activity of melatonin. Sleep, 23: 663-9.
41. STRECKER RE, MORAIRTY S, THAKKAR MM et al. (2000). Adenosinergique modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioural state. Behav Brain Res, 115: 183-204.
42. TAHERI S, ZEITZER JM, MIGNOT E. (2002). The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci, 25: 283-313.
43. THAKKAR MM, WINSTON S, MCCARLEY RW. (2002). Orexin neurons of the hypothalamus express adenosine A1 receptors. Brain Res, 944: 190-4.
44. A receptor subtype. Proc Natl Acad Sci, 98: 6464-69.
45. TOUSSAINT M, LUTHRINGER R, SCHALTENBRAND N et al. (1995). First-night effect in normal subjects and psychiatric inpatients. Sleep, 18: 463-9.
46. VGONTZAS AN, BIXLER EO, LIN HM et al. (2001). Chronic insomnia is associated with nycthemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocr Metab, 86: 3787-94.
47. VIOLA AU, BRANDENBERGER G, TOUSSAINT M, BOUHOURS P, MACHER JP, LUTHRINGER R. (2002). Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rythmicity in young poor sleepers. Clinical Neurophysiology, 113: 429-34.
48. WALSCH JK, VOGEL GW, SCHARF M et al. (2001). A five-week polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med, 1: 41-9.